Value Equation – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Value Equation

Josee

Science

Frequency: 1 episode/0d. Total Eps: 1

Hosted by Manda Li, Pricing and Commercialisation Analyst at SCIRIS Group, the series brings specialists from across SCIRIS Group's agencies into one conversation about the decisions that determine whether a strong medicine becomes a successful one.

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.buzzsprout.com/2649359/fan_mail/new
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 62%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

The cost of waiting: why early planning pays off

Season 1 · Episode 1

Friday, September 11, 2026 • Duration 40:05

Hosted by Manda Li, our Pricing and Commercialisation Analyst, the series brings specialists from across SCIRIS Group's agencies into one conversation about the decisions that determine whether a strong medicine becomes a successful one.

In episode one, "The cost of waiting: why early planning pays off," we're joined by:

David Eatwell, Global Head of Insight at Porterhouse Insights, on target product profile (TPP) testing, and why taking a medicine's assumptions out to clinicians and payers early can reshape trial design while there's still time to act.

Alec Miners, Head of Health Economics at Source Health Economics, on early cost-effectiveness modelling and working out an economically justifiable price long before phase three data exist, so companies know where their R&D budget is best spent.

Joe Wallis, Head of Pricing and Commercialisation at SCIRIS Group and co-host of the series, on why investors increasingly treat a credible TPP as a living investment roadmap, and why "regulatory approval means access" is now read as a red flag rather than reassurance.

The thread running through the conversation: waiting for trial results doesn't delay the consequences of decisions on comparators, endpoints and evidence. It only delays when you find out.

With joint clinical assessment and most favoured nation pricing reshaping the European landscape, that early planning window is getting shorter, not longer.

If you're planning a launch and want to talk through early commercialisation, get in touch.

Share your feedback & questions

Value Equation – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Value Equation – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Buzzsprout1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Buzzsprout1